About Invizius

Invizius provides dialysis and extra-corporeal treatments utilizing advanced filtration and purification technologies to effectively remove toxins from the blood of patients with kidney failure. This service meets the critical need for renal replacement therapy, enhancing patient outcomes and quality of life.

```xml <problem> Patients undergoing dialysis and other extracorporeal circuit therapies face the risk of inflammatory, fibrotic, and autoimmune disorders due to the activation of the complement system during these procedures. Current treatments do not adequately address this complement activation, leading to potential complications and reduced efficacy of the therapy. </problem> <solution> Invizius is developing second-generation complement therapeutics designed to mitigate the harmful effects of complement activation during extracorporeal treatments. Their lead product, H-Guard, is designed to harness and supercharge natural complement regulators to maximize patient safety and clinical efficacy. By targeting the complement system, H-Guard aims to reduce inflammation, fibrosis, and autoimmune responses, ultimately improving patient outcomes and tolerance of dialysis and other extracorporeal circuit therapies. The technology seeks to address the unmet needs of patients undergoing these treatments by providing a more targeted and effective approach to managing complement-mediated complications. </solution> <features> - Utilizes PspCN complement regulator technology to enhance the body's natural defenses. - Designed to minimize complement activation during dialysis and extracorporeal circuit therapies. - Aims to reduce inflammation, fibrosis, and autoimmune responses associated with complement activation. - H-Guard is the lead product currently in clinical development. </features> <target_audience> The primary target audience includes patients undergoing dialysis and other extracorporeal circuit therapies who are at risk of complement-mediated complications, as well as healthcare providers specializing in nephrology and related fields. </target_audience> ```

What does Invizius do?

When was Invizius founded?

Invizius was founded in 2018.

How much funding has Invizius raised?

Invizius has raised 1300000.

Founded

2018

Funding

1300000

Employees

15 employees

Major Investors

Mercia Ventures

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Invizius

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

invizius.com 1K+

Crunchbase

Founded 2018

Funding

Estimated Funding

$1M+

Major Investors

Mercia Ventures

Team (15+)

No team information available.

Company Description

Problem

Patients undergoing dialysis and other extracorporeal circuit therapies face the risk of inflammatory, fibrotic, and autoimmune disorders due to the activation of the complement system during these procedures. Current treatments do not adequately address this complement activation, leading to potential complications and reduced efficacy of the therapy.

Solution

Invizius is developing second-generation complement therapeutics designed to mitigate the harmful effects of complement activation during extracorporeal treatments. Their lead product, H-Guard, is designed to harness and supercharge natural complement regulators to maximize patient safety and clinical efficacy. By targeting the complement system, H-Guard aims to reduce inflammation, fibrosis, and autoimmune responses, ultimately improving patient outcomes and tolerance of dialysis and other extracorporeal circuit therapies. The technology seeks to address the unmet needs of patients undergoing these treatments by providing a more targeted and effective approach to managing complement-mediated complications.

Features

Utilizes PspCN complement regulator technology to enhance the body's natural defenses.

Designed to minimize complement activation during dialysis and extracorporeal circuit therapies.

Aims to reduce inflammation, fibrosis, and autoimmune responses associated with complement activation.

H-Guard is the lead product currently in clinical development.

Target Audience

The primary target audience includes patients undergoing dialysis and other extracorporeal circuit therapies who are at risk of complement-mediated complications, as well as healthcare providers specializing in nephrology and related fields.